Title

Phenobarbital for Acute Alcohol Withdrawal
Phenobarbital Versus Placebo for Acute Alcohol Withdrawal
  • Phase

    N/A
  • Study Type

    Interventional
  • Intervention/Treatment

    phenobarbital ...
  • Study Participants

    102
Intravenous phenobarbital in combination with a symptom-guided standardized lorazepam-based alcohol withdrawal protocol will be associated with decreased need for ICU admission, continuous lorazepam infusion and will not be associated with increased adverse events.
Study Started
Jan 31
2009
Primary Completion
Mar 31
2010
Study Completion
Mar 31
2010
Results Posted
Mar 09
2012
Estimate
Last Update
Mar 09
2012
Estimate

Drug 10 mg/kg IV phenobarbital in 100 ml saline

10 mg/kg IV phenobarbital in 100 ml saline

Drug placebo

100 m l saline

Phenobarbital group Active Comparator

10 mg/kg IV phenobarbital in 100 ml saline

Placebo group Placebo Comparator

100 ml saline

Criteria

Inclusion Criteria:

Need for admission to hospital for acute alcohol withdrawal

Exclusion Criteria:

allergy to phenobarbital, lorazepam, age<18 or >65

Summary

Phenobarbital Group

Placebo Group

All Events

Event Type Organ System Event Term

Number of Patients Requiring Continuous Lorazepam Infusion

All study patients are placed on the standardized institutional alcohol withdrawal protocol and receive boluses of lorazepam (1, 2 or 4 mg IV) based on their acute alcohol withdrawal score (AAWS), adminstered serially up to every 15 minutes. Patients who are refractory to the maximum dose of lorazepam allowed by the protocol (up to 4mg lorazepam IV q 15 mins)are placed on a continuous IV lorazepam infusion (or "lorazepam drip"). Thus, continuous lorazepam infusion is a "yes or no" variable (i.e. continuous infusion, or not).

Phenobarbital Group

2.0
participants

Placebo Group

16.0
participants

Percentage of Patients Requiring ICU Admission

admission to intensive care unit

Phenobarbital Group

8.0
percentage of participants

Placebo Group

25.0
percentage of participants

Total Lorazepam Required Per Patient Per Admission

How much total lorazepam did each study patient receive from inital presentation in the Emergency Department through their discharge from the hospital, in milligrams.

Phenobarbital Group

26.0
milligrams (Mean)
Standard Deviation: 45

Placebo Group

49.0
milligrams (Mean)
Standard Deviation: 37

Length of Stay

hospital LOS, per patient, in hours from admission to discharge

Phenobarbital Group

76.0
hours (Median)
Inter-Quartile Range: 54.0 to 114.0

Placebo Group

118.0
hours (Median)
Inter-Quartile Range: 47.0 to 190.0

Number of Patients Requiring Endotracheal Intubation as a Measure of Safety and Tolerability

The outome answeres the question "Did the study patient require endotracheal intubation, or not". This outcome investigates if the phenobarbital intervention is associted with increased incidence of respiratory depression and subsequent increased need for intubation.

Phenobarbital Group

Placebo Group

Percentage of Patients Requiring a Bedside Sitter as a Measure of Safety and Tolerability

Did the study patient require a Licensed Vocational Nurse (LVN) or other hospital staff to serve as a "bedside sitter" to observe the patient and provide additional safety supervision during any portion of their hospitalization.

Phenobarbital Group

28.0
percentage of participants

Placebo Group

22.0
percentage of participants

Number of Study Patients With Seizure as a Measure of Safety and Tolerability

Did the study patient have a witnessed seizure during their hospitaliztion (yes/no).

Phenobarbital Group

1.0
participants

Placebo Group

2.0
participants

Number of Study Patients With Mortality as a Measure of Safety and Tolerability

mortality in study patients

Phenobarbital Group

Placebo Group

Total

102
Participants

Age Continuous

47
years (Mean)
Standard Deviation: 14

Age, Categorical

Region of Enrollment

Sex: Female, Male

Overall Study

Phenobarbital Group

Placebo Group